RAD 2025: Yale dermatologist Mona Shahriari, MD, urged primary care clinicians to refer patients with AD who don't improve to prevent cumulative emotional burden.

ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.

ADA 2025: An intervention to emphasize weight-related care in primary care settings eliminated weight gain at the population level, researchers report.

Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.

ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.

Your daily dose of the clinical news you may have missed.

Advances in obesity pharmacotherapy will be the focus of numerous late-breaking science sessions at ADA 2025; snapshots of 5 studies follow.

The ADA unveils the association's first Standards of Care for Overweight and Obesity, with a chapter on weight stigma and bias one of the first released.

Dupilumab is the first targeted treatment for BP to receive FDA approval, showing improved remission rates, itch reduction, and lower steroid use in pivotal trial.

The investigational dual GLP-1/GLP-2 agonist led to 11.6% weight loss over 28 weeks with no lifestyle changes, showing strong safety and tolerability in the trial.